Trial | Studied treatment | Control treatment | patients | ROB | Result | NCT |
---|
|
AVF2119g (Miller) cape, 2005 | bevacizumab + capecitabine | capecitabine | | Risk of bias | Suggesting | |
Burstein, 2005 | bevacizumab + methotrexate | methotrexate | | | Negative | |
E2100 (Miller), 2007 | bevacizumab + taxanes | taxanes | | Risk of bias | Suggesting | NCT00028990 |
RIBBON-I (Robert) on top capecitabine, 2009 | bevacizumab + capecitabine | capecitabine | | | Suggesting | |
RIBBON-2 (Brufsky), 2009 | bevacizumav + CT | CT alone | | | Suggesting | |
AVADO (Miles) 15mg , 2009 | bevacizumab + docetaxel | docetaxel | | | Suggesting | |
RIBBON-I (Robert) on top Tax or anthra, 2009 | bevacizumab + taxanes | taxanes | | | Suggesting | |
AVADO (Miles) 7.5mg, 2010 | bevacizumab + docetaxel | docetaxel | | | Negative | |
Martin bevacizumab, 2011 | bevacizumab + paclitaxel | paclitaxel | | | Negative | |
|
Johnson, 2004 | bevacizumab | platinum based CT | | | - | |
Sandler, 2006 | bevacizumab | platinum based CT | | | - | |
Herbst, 2007 | bevacizumab | platinum based CT | | | - | |
Nishio, 2009 | bevacizumab | platinum based CT | | | - | |
Reck, 2010 | bevacizumab | | | | - | |
Herbst, 2011 | bevacizumab + erlotinib | erlotinib alone | | | - | |
|
Yang, 2003 | bevacizumab | placebo | | Exploratory | - | |
AVOREN, 2007 | bevacizumab plus interferon alfa | interferon alpha | | | Suggesting | |
CALGB 90206, 2010 | bevacizumab plus interferon alfa | interferon alpha | | | Suggesting | |